Literature DB >> 31009916

The treatment gap for mental disorders and associated factors in the Czech Republic.

Anna Kagstrom1, Aneta Alexova1, Eva Tuskova1, Zsófia Csajbók2, Georg Schomerus3, Tomas Formanek1, Karolína Mladá1, Petr Winkler4, Pavla Cermakova5.   

Abstract

OBJECTIVES: To assess the extent of the treatment gap for mental disorders in the Czech Republic, determine factors associated with the utilization of mental health services and explore what influences willingness to seek mental health care.
METHODS: Data from the CZEch Mental health Study, a nationally representative study of community-dwelling adults in the Czech Republic were used. The Mini International Neuropsychiatric Interview assessed the presence of mental disorders. 659 participants with current affective, anxiety, alcohol use and substance use disorders were studied.
RESULTS: The treatment gap for mental disorders ranged from 61% for affective to 93% for alcohol use disorders. Mental health service use was associated with greater disability (OR 1.04; 95% CI 1.02-1.05; p < 0.001), female gender (OR 3.31; 95% CI 1.97-5.57; p < 0.001), urban residence (OR 1.84; 95% CI 1.12-3.04; p < 0.05) and a higher number of somatic diseases (OR 1.32; 95% CI 1.03-1.67; p < 0.05). Self-identification as having a mental illness was associated with greater willingness to seek a psychiatrist and a psychologist.
CONCLUSIONS: The treatment gap for mental disorders is alarmingly high in the Czech Republic. Interventions to decrease it should target in particular rural areas, men and people with low self-identification as having a mental illness.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Central and Eastern Europe; Epidemiology; Mental disorders; Treatment gap

Year:  2019        PMID: 31009916     DOI: 10.1016/j.eurpsy.2019.04.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Prevalence, progress, and subgroup disparities in pharmacological antidepressant treatment of those who screen positive for depressive symptoms: A repetitive cross-sectional study in 19 European countries.

Authors:  Shanquan Chen; Tamsin J Ford; Peter B Jones; Rudolf N Cardinal
Journal:  Lancet Reg Health Eur       Date:  2022-03-28

2.  Mental Health of Czech University Psychology Students: Negative Mental Health Attitudes, Mental Health Shame and Self-Compassion.

Authors:  Yasuhiro Kotera; Denise Andrzejewski; Jaroslava Dosedlova; Elaina Taylor; Ann-Marie Edwards; Chris Blackmore
Journal:  Healthcare (Basel)       Date:  2022-04-02

3.  Education as inefficient resource against depressive symptoms in the Czech Republic: cross-sectional analysis of the HAPIEE study.

Authors:  Pavla Cermakova; Hynek Pikhart; Ruzena Kubinova; Martin Bobak
Journal:  Eur J Public Health       Date:  2020-10-01       Impact factor: 3.367

4.  Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan.

Authors:  Thomas Andrew Shepherd; Zia Ul-Haq; Mian Ul-Haq; Muhammad Firaz Khan; Adil Afridi; Lisa Dikomitis; Michelle E Robinson; Martyn Lewis; Atif Rahman; Krysia Dziedzic; Umaima Saeed; Naila Riaz Awan; Christian Mallen; Saeed Farooq
Journal:  BMJ Open       Date:  2020-06-30       Impact factor: 2.692

5.  Trajectories of depressive symptoms and associated patterns of cognitive decline.

Authors:  Tomáš Formánek; Zsófia Csajbók; Katrin Wolfová; Matěj Kučera; Sarah Tom; Dag Aarsland; Pavla Cermakova
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

6.  Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide cross-sectional surveys.

Authors:  P Winkler; T Formanek; K Mlada; A Kagstrom; Z Mohrova; P Mohr; L Csemy
Journal:  Epidemiol Psychiatr Sci       Date:  2020-09-29       Impact factor: 6.892

7.  Educational attainment inequalities in depressive symptoms in more than 100,000 individuals in Europe.

Authors:  Adam Chlapecka; Anna Kagstrom; Pavla Cermakova
Journal:  Eur Psychiatry       Date:  2020-11-16       Impact factor: 5.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.